Telaprevir activity in treatment-naive patients infected hepatitis C virus genotype 4: A randomized trial

Journal of Infectious Diseases

Volumn 208, Issue 6, 2013, Pages 1000-1007

  Benhamou, Yves ^a   Moussalli, Joseph ^a   Ratziu, Vlad ^a,b   Lebray, Pascal ^a   De Backer, Katrien ^c   De Meyer, Sandra ^c   Ghys, Anne ^c   Luo, Donghan ^d   Picchio, Gaston R ^d   Beumont, Maria ^c  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c JANSSEN RESEARCH FOUNDATION   (Belgium)

^d JANSSEN RESEARCH AND DEVELOPMENT   (United States)

Author keywords

HCV RNA; Study C210; SVR; viral kinetics

Indexed keywords

PEGINTERFERON ALPHA2A; PLACEBO; RIBAVIRIN; TELAPREVIR; VIRUS RNA;

ADULT; ALOPECIA; ANEMIA; ANORECTAL DISEASE; AREA UNDER THE CURVE; ARTICLE; ASTHENIA; CHOLELITHIASIS; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CONNECTIVE TISSUE DISEASE; CONSTIPATION; CONTROLLED STUDY; COUGHING; DECREASED APPETITE; DELIRIUM; DRUG EFFICACY; DRUG ERUPTION; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY SKIN; DYSPNEA; EYE DISEASE; FATIGUE; FEMALE; FLU LIKE SYNDROME; HEADACHE; HEPATITIS C; HUMAN; INFECTION; INFESTATION; MALAISE; MALE; MAXIMUM PLASMA CONCENTRATION; MENTAL DISEASE; MONOTHERAPY; MUSCULOSKELETAL DISEASE; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT OUTCOME; VASCULAR DISEASE; VIRUS LOAD; XEROSTOMIA;

HCV RNA; STUDY C210; SVR; VIRAL KINETICS;

ADOLESCENT; ADULT; AGED; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; OLIGOPEPTIDES; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RIBAVIRIN; RNA, VIRAL; VIRAL LOAD; YOUNG ADULT;

EID: 84883227555     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jit274     Document Type: Article

References (37)

1. Simmonds P. Genetic diversity and evolution of hepatitis C virus-15 years on. J Gen Virol 2004; 85:3173-88.
2. NIH consensus statement on management of hepatitis C: 2002. NIH Consens State Sci Statements 2002; 19:1-46.
3. Simmonds P, Bukh J, Combet C, et al. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology 2005; 42:962-73.
4. Hnatyszyn HJ. Chronic hepatitis C and genotyping: the clinical significance of determining HCV genotypes. Antiver Ther 2005; 10:1-11.
5. Robertson B, Myers G, Howard C, et al. Classification, nomenclature, and database development for hepatitis C virus (HCV) and related viruses: proposals for standardization. International Committee on Virus Taxonomy. Arch Virol 1998; 143:2493-503.
6. Nguyen MH, Keeffe EB. Prevalence and treatment of hepatitis C virus genotypes 4, 5, and. Clin Gastroenterol Hepatol 2005; 3:S97-101.
7. Sievert W, Altraif I, Razavi HA, et al. A systematic review of hepatitis C virus epidemiology in Asia, Australia and Egypt. Liver Int 2011; 31(Suppl. 2):61-80.
8. Abdel-Aziz F, Habib M, Mohamed MK, et al. Hepatitis C virus (HCV) infection in a community in the Nile Delta: population description and HCV prevalence. Hepatology 2000; 32:111-5.
9. Payan C, Roudot-Thoraval F, Marcellin P, et al. Changing of hepatitis C virus genotype patterns in France at the beginning of the third millenium: The GEMHEP GenoCII Study. J Viral Hep 2005; 12:405-13.
10. Nicot F, Legrand-Abravanel F, Sandres-Saune K, et al. Heterogeneity of hepatitis C virus genotype 4 strains circulating in south-western France. J Gen Virol 2005; 86:107-14.
11. Ansaldi F, Bruzzone B, Salmaso S, et al. Different seroprevalence and molecular epidemiology patterns of hepatitis C virus infection in Italy. J Med Virol 2005; 76:327-32.
12. Katsoulidou A, Sypsa V, Tassopoulos NC, et al. Molecular epidemiology of hepatitis C virus (HCV) in Greece: temporal trends in HCV genotype-specific incidence and molecular characterization of genotype 4 isolates. J Viral Hep 2006; 13:19-27.
13. Fernández-Arcás N, López-Siles J, Trapero S, et al. High prevalence of hepatitis C virus subtypes 4c and 4d in Malaga (Spain): phylogenetic and epidemiological analyses. J Med Virol 2006; 78:1429-35.
14. Franco S, Tural C, Clotet B, MartínezMA. Complete nucleotide sequence of genotype 4 hepatitis C viruses isolated from patients co-infected with human immunodeficiency virus type. Virus Res 2007; 123:161-9.
15. Rapicetta M, Argentini C, Dettori S, Spada E, Pellizzer G, Gandin C. Molecular heterogeneity and new subtypes of HCV genotype 4. Res Virol 1998; 149:293-7.
16. Ghany M, Nelson DR, Strader DB, Thomas DL, Seeff LB; American Association for Study of Liver Diseases. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 2011; 54:1433-4.
17. Kamal SM, Nasser IA. Hepatitis C genotype 4: what we know and what we don't yet know. Hepatology 2008; 47:1371-83.
18. Roulot D, Bourcier V, Grando V, et al. Epidemiological characteristics and response to peginterferon plus ribavirin treatment of hepatitis C virus genotype 4 infection. J Viral Hep 2007; 14:460-7.
19. Sherman KE, Flamm SL, Afdhal NH, et al. Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med 2011; 365:1014-24.
20. Foster GR, Hézode C, Bronowicki J-P, et al. Telaprevir alone or with peginterferon and ribavirin reduces HCV RNA in patients with chronic genotype 2 but not genotype 3 infections. Gastroenterology 2011; 141:881-9.
21. Forestier N, Reesink HW, Weegink CJ, et al. Antiviral activity of telaprevir (VX-950) and peginterferon alfa-2a in patients with hepatitis C. Hepatology 2007; 46:640-8.
22. Zeuzem S, Andreone P, Pol S, et al. Telaprevir for retreatment of HCV infection. N Engl J Med 2011; 364:2417-28.
23. Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364:2405-16.
24. McHutchison JG, Everson GT, Gordon SC, et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med 2009; 360:1827-38.
25. Hézode C, Forestier N, Dusheiko G, et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med 2009; 360:1839-50.
26. Marcellin P, Forns X, Goeser T, et al. Telaprevir is effective given every 8 or 12 hours with ribavirin and peginterferon alfa-2a or-2b to patients with chronic hepatitis C. Gastroenterology 2011; 140:459-68.
27. European Medicines Agency. Incivo (telaprevir) tablets. Annex I: summary of product characteristics. October 2011. http://www.ema. europa.eu/docs/en-GB/ document-library/EPAR---Product-Information/human/002313/WC500115529.pdf. Accessed 28 June 2013.
28. Incivek (telaprevir) tablets. FDA prescribing information. 2011. Available at: http://pi.vrtx.com/files/uspi-telaprevir.pdf. Accessed 28 June 2013.
29. Lin C, Hanzelka BL, Muh U, et al. Telaprevir (VX-950) is a potent inhibitor of HCV NS3-4A proteases derived from genotype non-1 HCV infected patients. J Hepatol 2007; 46(Suppl S1):S8.
30. Kieffer TL, Sarrazin C, Miller JS, et al. Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients. Hepatology 2007; 46:631-9.
31. McOmish F, Yap PL, Dow BC, et al. Geographical distribution of hepatitis C virus genotypes in blood donors: an international collaborative survey. J Clin Microbiol 1994; 32:884-92.
32. Ray SC, Arthur RR, Carella A, Bukh J, Thomas DL. Genetic epidemiology of hepatitis C virus throughout Egypt. J Infect Dis 2000; 182:698-707.
33. Forestier N, Zeuzem S. Telaprevir for the treatment of hepatitis C. Expert Opin Pharmacother 2012; 13:593-606.
34. Pineda JA, Caruz A, Rivero A, et al. Prediction of response to pegylated interferon plus ribavirin by IL28B gene variation in patients coinfected with HIV and hepatitis C virus. Clin Infect Dis 2010; 51:788-95.
35. Thompson AJ, Muir AJ, Sulkowski MS, et al. Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology 2010; 139:120-9.
36. Rivero-Juárez A, Camacho Espejo A, Perez-Camacho I, et al. Association between the IL28B genotype and hepatitis C viral kinetics in the early days of treatment with pegylated interferon plus ribavirin in HIV/HCV co-infected patients with genotype 1 or 4. J Antimicrob Chemother 2012; 67:202-5.
37. Fried MW. The role of triple therapy in HCV genotype 1-experienced patients. Liver Int 2011; 31(Suppl. 1):58-61.